Generic name
Dextromethorphan hydrobromide: adverse event reports filed with FDA
1,670 reports list it as a suspect or interacting product, 2004–2026. Class: Expectorant.
- 1,670
- reports as suspect product
- 0% of all reports · about 75 a year
- 116
- reports, 12 months to June 2026
- 167 in the 12 months before
- 75.5%
- marked serious by the reporter
- 33.2% across the class
- 46.8%
- record death among outcomes, as reported
- 782 reports · not verified by FDA
1,670 adverse event reports received by FDA list dextromethorphan hydrobromide, a generic name as a suspect or interacting product, from February 2004 to June 2026. A further 1,120 reports list it only as a concomitant medication, and those are not counted in the figures on this page.
In the 12 months to June 2026, 116 reports listed it, down 31% from 167 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 75 reports a year and 0% of the 20,646,523 reports in the database, and 3.3% of the reports for the expectorant class. How many people take it is not in the data, so a count is not a rate of occurrence.
Reporters most often recorded drug abuse (15.9%), toxicity to various agents (13.8%) and drug ineffective (10.6%). A report can list several reactions, so shares add to more than 100%; 507 different terms appear across these reports. Drug abuse is recorded in 15.9% of these reports, a larger share than in the median expectorant drug (0.9%).
75.5% of the reports are marked serious by the reporter (33.2% across the class); 46.8% record death among the outcomes and 24% record hospitalisation, as reported. 33.8% of the reports came from physicians, and the largest patient age group is 18 to 44 (34.4%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Dextromethorphan hydrobromide reports recording the termmedian drug in expectorant
- Drug abusemisuse of a medicine15.9%265
- Toxicity to various agentspoisoning or toxic effect of one or more substances13.8%231
- Drug ineffectivethe medicine did not work as expected10.6%177
- Completed suicidedeath by suicide10.5%176
- Intentional overdosea deliberate overdose4.8%80
- Drug interactionan interaction between medicines4.7%78
- Drug toxicity4.4%74
- Intentional product misusedeliberate use not as intended4.4%73
- Cardiac arrestthe heart stopped4.1%69
- Respiratory arrestbreathing stopped4.1%68
- Deaththe patient died; cause not stated by this term4%67
- Serotonin syndrometoo much serotonin activity, with agitation, fever and tremor4%67
- Exposure during pregnancythe medicine was taken during pregnancy3.9%65
- Diarrhoealoose or frequent stools3.7%62
- Fatiguetiredness3.7%61
- Condition aggravatedthe condition being treated got worse3.6%60
- Confusional stateconfusion3.5%58
- Off label useused for a purpose or in a way not on the label3.5%58
- Insomniadifficulty sleeping3.4%57
- Dizzinesslight-headedness or unsteadiness3.4%56
- Overdosea dose above the recommended amount3.4%56
- Cardio-respiratory arrestthe heart and breathing stopped3.3%55
- Pyrexiafever3.2%54
- Weight increasedweight gain3.2%54
- Dyspnoeashortness of breath3.1%52
- Hypertensionhigh blood pressure3.1%51
- Vomitingbeing sick3.1%51
- Injurya physical injury3%50
- Sleep disordera sleep problem2.8%47
- Joint swellinga swollen joint2.8%46
Top 30 of 507 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 10 drugs in the expectorant class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 51,345 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 67.5% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Cough | 294 | 17.6% |
| Complex regional pain syndrome | 25 | 1.5% |
| Nasopharyngitis | 21 | 1.3% |
| Suicide attempt | 20 | 1.2% |
| Antitussive therapy | 15 | 0.9% |
| Rheumatoid arthritis | 15 | 0.9% |
The indication field is filled in by the reporter and is often blank; shares are of all 1,670 reports.
Drugs most often listed in the same reports
| Drug (any role in the report) | Reports | Share of Dextromethorphan hydrobromide reports |
|---|---|---|
| Acetaminophen | 258 | 15.4% |
| Ibuprofen | 134 | 8% |
| Codeine | 115 | 6.9% |
| Oxycodone | 100 | 6% |
| Pseudoephedrine hydrochloride | 95 | 5.7% |
| Diclofenac | 88 | 5.3% |
| Diclofenac sodium | 84 | 5% |
| Heroin | 80 | 4.8% |
| Prednisone | 77 | 4.6% |
| Cocaine | 74 | 4.4% |
Other products listed in reports where Dextromethorphan hydrobromide is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.
In context
| Measure | Dextromethorphan hydrobromide | Expectorant | All reports |
|---|---|---|---|
| Reports as suspect product | 1,670 | 51,345 | 20,646,523 |
| Share of that pool | — | 3.3% | 0% |
| Reports, latest 12 months | 116 | — | 1,332,454 |
| Marked serious | 75.5% | 33.2% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 468 | 50 | 91 |
| Hospitalisation recorded, per 1,000 reports | 240 | 96 | 213 |
| Consumer-filed share | 26.2% | 80.8% | 45.8% |
| Top term, share of reports | Drug abuse 15.9% | median 0.9% | 0.4% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the expectorant class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Tylenol | brand | 30,726 | 5,536 | 39.8% |
| Mucinex | brand | 5,107 | 351 | 19.8% |
| Delsym | brand | 3,579 | 144 | 15% |
| Mucinex Dm Maximum Strength | brand | 3,328 | 177 | 11.5% |
| Mucinex DM | brand | 2,422 | 119 | 28% |
| Mucinex Maximum Strength | brand | 2,227 | 187 | 7.1% |
| Guaifenesin | generic | 1,208 | 108 | 45.6% |
| Dextromethorphan hydrobromide,guaifenesin | generic | 576 | 139 | 12.7% |
| Mucinex D | brand | 502 | 24 | 34.1% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Dextromethorphan hydrobromide reports
How many adverse event reports has FDA received for Dextromethorphan hydrobromide?
1,670 reports list Dextromethorphan hydrobromide as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 116 of them arrived in the latest 12 months. Another 1,120 list it only as a concomitant medication.
What reactions are recorded in Dextromethorphan hydrobromide reports?
drug abuse (15.9%), toxicity to various agents (13.8%), drug ineffective (10.6%), completed suicide (10.5%) and intentional overdose (4.8%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Dextromethorphan hydrobromide was responsible.
How serious are the reports?
75.5% are marked serious by the reporter. Among the outcomes recorded, 46.8% of reports include death and 24% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
physician (33.8%), other health professional (30.5%) and consumer or non-health professional (26.2%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Dextromethorphan hydrobromide rising?
116 reports in the 12 months to June 2026, down 31% from 167 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Dextromethorphan hydrobromide was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Dextromethorphan hydrobromide?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Dextromethorphan hydrobromide as a suspect or interacting product; reports listing it only as a concomitant medication (1,120) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.